Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 15/20 | 0.64 |
| ▸ | CARM1 | Q86X55 | 3/20 | 0.53 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.52 |
| ▸ | F10 | P00742 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18605004 | 0.91 | KLKB1 (0.66) | KLKB1 | |
| SCHEMBL18604707 | 0.87 | KLKB1 (0.66) | KLKB1CARM1 | |
| SCHEMBL29826481 | 0.87 | KLKB1 (0.66) | KLKB1CARM1 | |
| SCHEMBL17064924 | 0.87 | KLKB1 (0.64) | KLKB1 | |
| SCHEMBL18630541 | 0.86 | KLKB1 (0.62) | KLKB1 | |
| SCHEMBL18632732 | 0.86 | KLKB1 (0.62) | KLKB1 | |
| SCHEMBL18604889 | 0.86 | KLKB1 (0.64) | KLKB1CARM1F10 | |
| SCHEMBL18604664 | 0.86 | KLKB1 (0.69) | KLKB1 | |
| SCHEMBL31067428 | 0.86 | KLKB1 (0.64) | KLKB1CARM1F10 | |
| SCHEMBL18604975 | 0.85 | KLKB1 (0.66) | KLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10689346-B2 | Human plasma kallikrein inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2020-06-23 | — | — | US | disclosed |
| US-20190322626-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2019-10-24 | — | — | US | disclosed |
| US-10329260-B2 | Human plasma kallikrein inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2019-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10329260-B2 | Human plasma kallikrein inhibitors | KLKB1, KLK1, KLK5 | KLKB1 1/4885CARM1 4366/4885NPY5R 2056/4885 |
| US-20190322626-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK1, KLK5 | KLKB1 1/4885CARM1 4366/4885NPY5R 2056/4885 |
| US-10689346-B2 | Human plasma kallikrein inhibitors | KLKB1, KLK1, KLK5 | KLKB1 1/4885CARM1 4366/4885NPY5R 2056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.